• Pharmaceutical Chemical Hot Quality Ibrutinib Ibrutinib N-2 Ibrutinib N-3
  • Pharmaceutical Chemical Hot Quality Ibrutinib Ibrutinib N-2 Ibrutinib N-3
  • Pharmaceutical Chemical Hot Quality Ibrutinib Ibrutinib N-2 Ibrutinib N-3
  • Pharmaceutical Chemical Hot Quality Ibrutinib Ibrutinib N-2 Ibrutinib N-3
  • Pharmaceutical Chemical Hot Quality Ibrutinib Ibrutinib N-2 Ibrutinib N-3

Pharmaceutical Chemical Hot Quality Ibrutinib Ibrutinib N-2 Ibrutinib N-3

Powder: Yes
Customized: Customized
Certification: GMP, HSE, ISO 9001, USP, BP
Suitable for: Elderly, Children, Adult
State: Powder,in Stock!!!Same Day Shipping!!
Purity: >99%, 99%
Samples:
US$ 1/g 1 g(Min.Order)
| Request Sample
Customization:
Diamond Member Since 2021

Suppliers with verified business licenses

Rating: 5.0/5
Manufacturer/Factory
  • Overview
  • Product Description
  • Detailed Photos
  • Packaging & Shipping
  • Our Advantages
  • Company Profile
  • Certifications
  • FAQ
Overview

Basic Info.

Model NO.
ibrutinib
Type
Pharmaceutical Intermediates
Appearance
Powder
Quality
Technical
Colour
White
CAS No.
936563-96-1
Formula
C25h24n6o2
Einecs
CB12515873
Assay
99%
Product Name
Ibrutinib
Appearanc
White to off-White Powder
Storage
Cool Dry Place, Room Temp
Expiration Date
3 Years
Company
Manufacturer
Total Impurities
0.27%
Single Impurity
0.04%
Loss on Drying
0.05%
Residue on Ignition
0.07%
Transport Package
Foil Bag; Fiber Drum
Specification
10g 50g 100g 1kg 25kg 100kg 500kg
Origin
Shangdong
Production Capacity
500kg/Month

Product Description

Jinan Jianfeng Chemical Co., Ltd
 

Product Description

Pharmaceutical Chemical Hot Quality Ibrutinib Ibrutinib N-2 Ibrutinib N-3

 

Product introduction:

CAS: 936563-96-1

MF: C25H24N6O2

Loss on drying: ≤1.0%

Purity: ≥99.0%

Description: Purity 99% Ibrutinib powder cas 936563-96-1 is an inhibitor of Bruton tyrosine kinase (BTK) for the treatment of chronic lymphoblastic leukemia (CLL) and sleeve cell lymphoma (MCL).

Application:

1. Purity 99% Ibrutinib powder cas 936563-96-1 is used for Chronic graft-versus-host (cGVHD) disease after failure of one or more prior lines of systemic therapy.

2. Chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

3. Mantle cell lymphoma (MCL) who have received at least one prior therapy.

4. Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.

5. Waldenstrom's macroglobulinemia.

 

Detailed Photos

Pharmaceutical Chemical Hot Quality Ibrutinib Ibrutinib N-2 Ibrutinib N-3

Packaging & Shipping

Pharmaceutical Chemical Hot Quality Ibrutinib Ibrutinib N-2 Ibrutinib N-3

Our Advantages

Pharmaceutical Chemical Hot Quality Ibrutinib Ibrutinib N-2 Ibrutinib N-3
1. Goverment support guarantees good company credibility and finance safe.

2. Jianfeng Chemical is confident at the product quality, and would like t o supply free sample.

3. Factory locates in national new material industrial park where guarantees safe and continuous production.

4. More than 10 years chemical production and exporting experience, and good relationship with customs and ship agents, which guarantee fast and safe export.

5. Professional R&D technology team and equipment which keep products quality better and better.

6. Timely afterservice resolves your worry for international trade.

 

 

Company Profile

Pharmaceutical Chemical Hot Quality Ibrutinib Ibrutinib N-2 Ibrutinib N-3Pharmaceutical Chemical Hot Quality Ibrutinib Ibrutinib N-2 Ibrutinib N-3

Certifications

Pharmaceutical Chemical Hot Quality Ibrutinib Ibrutinib N-2 Ibrutinib N-3
Pharmaceutical Chemical Hot Quality Ibrutinib Ibrutinib N-2 Ibrutinib N-3

FAQ

Pharmaceutical Chemical Hot Quality Ibrutinib Ibrutinib N-2 Ibrutinib N-3

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

You Might Also Like

Diamond Member Since 2021

Suppliers with verified business licenses

Rating: 5.0/5
Manufacturer/Factory
Number of Employees
13
Year of Establishment
2011-07-26